Eliot Godofsky
Overview
Explore the profile of Eliot Godofsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joseph P, Godofsky E
Open Forum Infect Dis
. 2018 Feb;
5(2):ofy024.
PMID: 29479553
Background: The majority of oral antibiotics are prescribed in outpatient primary and urgent care clinics for acute respiratory infections. Effective antibiotic stewardship must include proper prescribing for outpatients as well...
2.
Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, et al.
Hepatology
. 2015 Dec;
64(2):360-9.
PMID: 26704148
Unlabelled: Hepatitis C virus (HCV)-infected patients with cirrhosis are historically a difficult-to-treat population and are at risk of hepatic decompensation. In the phase 2 COSMOS study that evaluated simeprevir (HCV...
3.
Anderson D, Harris S, Godofsky E, Toriscelli T, Rude T, Elder K, et al.
Open Forum Infect Dis
. 2015 Mar;
1(3):ofu096.
PMID: 25734164
Two American football players on the same team were diagnosed with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections on the same day. Our investigation, including whole genome sequencing,...
4.
Lalezari J, Box T, ORiordan W, Mehra P, Nguyen T, Poordad F, et al.
Antivir Ther
. 2013 Feb;
18(6):755-64.
PMID: 23439365
Background: IDX184 is a liver-targeted nucleotide prodrug that selectively inhibits HCV NS5B polymerase. Methods: This randomized, double-blind, placebo-controlled, ascending-dose study investigated the antiviral activity, safety and pharmacokinetics of IDX184 plus...
5.
Godofsky E
Infect Dis Clin North Am
. 2012 Oct;
26(4):839-47.
PMID: 23083818
Hepatitis C virus (HCV) has evolved into a true infectious disease that needs the increased involvement of infectious disease (ID) physicians. HCV is a serious public health concern requiring screening,...
6.
Wedemeyer H, Jensen D, Godofsky E, Mani N, Pawlotsky J, Miller V
Hepatology
. 2012 Jun;
56(6):2398-403.
PMID: 22707382
Outdated virological response terms used at key trial timepoints in clinical trials with first-generation direct-acting antivirals plus pegylated interferon and ribavirin have failed to keep pace with hepatitis C virus...
7.
Lawitz E, Godofsky E, Rouzier R, Marbury T, Nguyen T, Ke J, et al.
Antiviral Res
. 2011 Jan;
89(3):238-45.
PMID: 21255610
Background: Cyclophilin inhibitors have shown activity against a variety of viruses, including HCV. NIM811, a novel, non-immunosuppressive cyclophilin inhibitor was studied in ascending doses in a randomized, double-blind, placebo-controlled 14-day...
8.
Jacobson J, Kuritzkes D, Godofsky E, DeJesus E, Larson J, Weinheimer S, et al.
Antimicrob Agents Chemother
. 2008 Nov;
53(2):450-7.
PMID: 19015347
Ibalizumab (formerly TNX-355) is a humanized monoclonal antibody that binds CD4, the primary receptor for human immunodeficiency virus type 1 (HIV-1), and inhibits the viral entry process. A phase lb...
9.
Pockros P, Nelson D, Godofsky E, Rodriguez-Torres M, Everson G, Fried M, et al.
Hepatology
. 2008 Sep;
48(4):1349-50.
PMID: 18821613
No abstract available.
10.
Pockros P, Nelson D, Godofsky E, Rodriguez-Torres M, Everson G, Fried M, et al.
Hepatology
. 2008 Jun;
48(2):385-97.
PMID: 18570306
Unlabelled: R1626, a prodrug of the hepatitis C virus (HCV) RNA polymerase inhibitor R1479, showed time-dependent and dose-dependent reduction of HCV RNA levels in a previous study. The present study...